2696 — Shanghai Henlius Biotech Share News
0.000.00%
Last trade - 00:00- HK$35.72bn
- HK$39.39bn
- CNY6.67bn
Shanghai Henlius hits 7-week peak after regulator's nod for new drug application
Brief: Shanghai Henlius Biotech Receives NMPA Approval For Ind Application For Hlxte-Haase02 Phase 1 Trial
Brief: Shanghai Henlius Biotech FY Profit Attributable Rmb827 Million
Brief: Shanghai Henlius Biotech Says NMPA Approves IND Application For Phase 1 Trial Of Nivolumab Biosimilar HLX18
Brief: Shanghai Henlius Biotech Inc Says NMPA Approves IND Application For Hlx07 And Hansizhuang Combination In SQNSCLC
Shanghai Henlius Biotech rises most in 5 months on new drug application
Brief: Shanghai Henlius Biotech Says NMPA Approves IND Application For Phase 1 Trial HLX316
Brief: Shanghai Henlius Biotech Says FDA Approves IND Application For Hlx15-SC For Multiple Myeloma
Eisai strikes Japan licensing deal with Shanghai Henlius Biotech (updated)
Eisai strikes Japan licensing deal with Shanghai Henlius Biotech
Brief: Shanghai Henlius Biotech Announces License Agreement With Eisai
Brief: Fosun Pharma Says Henlius Signs Licensing Agreement With Eisai
Shanghai Henlius jumps most in 3-1/2 months on tumour drug trial approval
Brief: Shanghai Henlius Biotech Says Application For Clinical Trial Of HLX43 For Injection Approved
Brief: Shanghai Henlius Biotech Says Application For Phase 1B/2 Hlx701 Clinical Trial approved
Brief: Shanghai Henlius Biotech Says Biologics License Application For Hanbeitai (Bevacizumab Injection) Accepted By FDA
Brief: Shanghai Henlius Biotech Says Phase 1 Clinical Trial Of Nivolumab Biosimilar HLX18 Approved By FDA
Brief: Shanghai Henlius Biotech Says NDA For Hansizhuang Granted Priority Review By NMPA
Brief: Shanghai Henlius Biotech Inc Says Jinzhou Avanc Pharmaceutical To Grant Exclusive License